CONTRAFECT CORP

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch CFRXQ and buy or sell other stocks, ETFs, and their options commission-free!

About CFRXQ

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. 

CEO
Michael Messinger, CPA
CEOMichael Messinger, CPA
Employees
23
Employees23
Headquarters
Yonkers, New York
HeadquartersYonkers, New York
Founded
2008
Founded2008
Employees
23
Employees23

CFRXQ Key Statistics

Market cap
1.07K
Market cap1.07K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
32.60
Average volume32.60
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.0005
52 Week high$0.0005
52 Week low
$0.00
52 Week low$0.00

Stock Snapshot

CONTRAFECT CORP(CFRXQ) stock is priced at $0.00, giving the company a market capitalization of 1.07K.

During the trading day, CONTRAFECT CORP(CFRXQ) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 32.6.

The stock's 52-week range extends from a low of $0.00 to a high of $0.00.

The stock's 52-week range extends from a low of $0.00 to a high of $0.00.

People also own

Based on the portfolios of people who own CFRXQ. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.